

## Special Issue

# Advances in Immunotherapy for T Cells and Tumors

### Message from the Guest Editor

Cancer is a devastating disease which has been and continues to be one of the main threats to human health. Traditional cancer treatments, including surgery, chemotherapy, and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. In addition, chemotherapy and radiotherapy often cause considerable side effects. Therefore, innovative and effective cancer treatments are urgently needed for cancer patients with late-stage and refractory disease. Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. This Special Issue welcomes reviews, as well as original articles related to research on a broad range of immunotherapy treatments, including cellular therapies, vaccines, and ICB; the identification of new predictive biomarkers and therapeutic targets; novel therapeutic approaches; and the use of immune modulators to overcome immune resistance, among others.

---

### Guest Editor

Dr. Zhichen Sun

UT Southwest Medical Center, Dallas, TX, USA

---

### Deadline for manuscript submissions

closed (15 March 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/150549](https://mdpi.com/si/150549)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).